Aref Al-Kali, Hematologist/Oncologist at Mayo Clinic, shared a post on X, adding:
“I mentioned this abstract a year ago. Now published in Blood Journal.
New concept and potential biological subgroup -RUNX1- that benefit the most.”
Authors: Yuchen Liu et al.
Quoting his original post:
“PegC plus VEN in patients with rrAML has activity esp in RUNX1m. Excellent work and new front on targeting oncometabolome.”
